Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,138 | 525 | 88.3% |
| Travel and Lodging | $1,021 | 7 | 9.9% |
| Grant | $142.86 | 1 | 1.4% |
| Education | $36.98 | 2 | 0.4% |
| Entertainment | $9.20 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,694 | 89 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,018 | 77 | $0 (2024) |
| Olympus Corporation of the Americas | $968.78 | 10 | $0 (2023) |
| Boston Scientific Corporation | $928.69 | 30 | $0 (2024) |
| Janssen Biotech, Inc. | $624.73 | 39 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $449.28 | 29 | $0 (2023) |
| PFIZER INC. | $357.06 | 27 | $0 (2019) |
| Apollo Endosurgery US Inc | $337.07 | 5 | $0 (2018) |
| Allergan Inc. | $332.32 | 28 | $0 (2019) |
| Braintree Laboratories, Inc. | $304.40 | 11 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $449.02 | 22 | ABBVIE INC. ($119.14) |
| 2023 | $2,145 | 71 | Olympus Corporation of the Americas ($968.78) |
| 2022 | $1,399 | 78 | ABBVIE INC. ($529.71) |
| 2021 | $1,268 | 68 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($454.71) |
| 2020 | $652.20 | 24 | Endogastric Solutions, Inc ($286.64) |
| 2019 | $1,156 | 67 | Janssen Biotech, Inc. ($241.86) |
| 2018 | $1,637 | 95 | Apollo Endosurgery US Inc ($337.07) |
| 2017 | $1,642 | 111 | AbbVie, Inc. ($206.81) |
All Payment Transactions
536 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Immunology | ||||||
| 11/15/2024 | CapsoVision, Inc. | CapsoCam Plus (Device) | Food and Beverage | Cash or cash equivalent | $17.49 | General |
| Category: Gastroenterology | ||||||
| 10/09/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Obesity | ||||||
| 09/11/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: VIROLOGY | ||||||
| 08/07/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Neurology | ||||||
| 08/06/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $15.29 | General |
| 08/01/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: Immunology | ||||||
| 07/31/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Obesity | ||||||
| 06/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), PLENVU | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Gastroenterology | ||||||
| 06/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Obesity | ||||||
| 05/20/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Diabetes | ||||||
| 05/15/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), PLENVU | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Gastroenterology | ||||||
| 05/09/2024 | Boston Scientific Corporation | EXALT Model D (Device) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: EXALT Model D_ENDO | ||||||
| 04/19/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.44 | General |
| Category: Neuroscience | ||||||
| 03/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.97 | General |
| Category: Neuroscience | ||||||
| 03/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.55 | General |
| Category: IMMUNOLOGY | ||||||
| 03/06/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $22.86 | General |
| 02/08/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: VIROLOGY | ||||||
| 01/31/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: IMMUNOLOGY | ||||||
| 01/23/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Obesity | ||||||
| 01/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: IMMUNOLOGY | ||||||
| 01/12/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.26 | General |
| Category: Neuroscience | ||||||
| 12/20/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $3.91 | General |
| Category: Neuroscience | ||||||
| 12/08/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $12.83 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 800 | 2,035 | $396,050 | $87,544 |
| 2022 | 14 | 898 | 1,048 | $449,122 | $111,579 |
| 2021 | 15 | 827 | 975 | $414,568 | $104,720 |
| 2020 | 13 | 661 | 779 | $316,232 | $74,287 |
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 145 | 210 | $70,818 | $21,315 | 30.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 81 | 84 | $42,504 | $11,590 | 27.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 79 | 79 | $34,460 | $10,187 | 29.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 86 | 87 | $84,867 | $9,028 | 10.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 96 | $22,756 | $6,290 | 27.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 27 | 27 | $34,811 | $6,203 | 17.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 65 | 84 | $15,300 | $5,602 | 36.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 46 | $12,435 | $4,624 | 37.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 34 | 34 | $43,115 | $4,473 | 10.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 20 | 21 | $17,099 | $2,985 | 17.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 11 | 11 | $10,153 | $2,009 | 19.8% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 26 | 31 | $3,968 | $1,559 | 39.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 25 | 30 | $1,800 | $768.60 | 42.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 49 | 63 | $725.00 | $503.44 | 69.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 16 | 19 | $361.00 | $144.59 | 40.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 11 | 13 | $338.00 | $134.55 | 39.8% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 11 | 1,100 | $540.00 | $128.65 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 138 | 184 | $61,640 | $18,831 | 30.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 72 | 77 | $38,962 | $13,262 | 34.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 125 | 180 | $42,480 | $12,895 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 92 | 92 | $40,020 | $12,021 | 30.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 45 | 45 | $48,684 | $10,230 | 21.0% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 14 | 14 | $32,284 | $9,987 | 30.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 85 | 86 | $76,125 | $9,333 | 12.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 44 | 45 | $46,176 | $5,904 | 12.8% |
About Dr. Tamer Sargios, MD
Dr. Tamer Sargios, MD is a Gastroenterology healthcare provider based in Poughkeepsie, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1376520700.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tamer Sargios, MD has received a total of $10,349 in payments from pharmaceutical and medical device companies, with $449.02 received in 2024. These payments were reported across 536 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($9,138).
As a Medicare-enrolled provider, Sargios has provided services to 3,186 Medicare beneficiaries, totaling 4,837 services with total Medicare billing of $378,130. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Poughkeepsie, NY
- Active Since 12/28/2005
- Last Updated 07/21/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1376520700
Products in Payments
- Single Use Electrosurgical Knife KD-655 (Device) $968.78
- XIFAXAN (Drug) $881.57
- STELARA (Biological) $582.50
- RINVOQ (Biological) $543.53
- SKYRIZI (Biological) $371.10
- Overstitch (Device) $337.07
- ESOPHYX (Device) $286.64
- LINZESS (Drug) $280.26
- GENERAL PAIN MANAGEMENT (Device) $273.41
- Humira (Biological) $271.63
- EXALT Model D (Device) $253.10
- XELJANZ (Drug) $247.41
- Cimzia (Drug) $246.43
- ZEPOSIA (Drug) $231.07
- Saxenda (Drug) $209.70
- Amitiza (Drug) $190.61
- NASCOBAL (Drug) $183.80
- HUMIRA (Biological) $175.94
- Trulance (Drug) $171.10
- Mavyret (Drug) $150.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Poughkeepsie
Anthony Starpoli, M.d, M.D
Gastroenterology — Payments: $47,720
Dr. Robert Dean, Md, MD
Gastroenterology — Payments: $37,658
Dr. Peter Varunok, Md, MD
Gastroenterology — Payments: $35,234
Ravi Hotchandani, Md, MD
Gastroenterology — Payments: $28,261
Dr. Salvatore Buffa, Md, MD
Gastroenterology — Payments: $13,778
Dr. Farah Toyserkani, Md, MD
Gastroenterology — Payments: $10,977